{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/chest-infections-adult/prescribing-information/erythromycin/","result":{"pageContext":{"chapter":{"id":"b500954c-b6b0-5e3b-ac55-0c2c6e2faf4c","slug":"erythromycin","fullItemName":"Erythromycin","depth":2,"htmlHeader":"<!-- begin field 3ecd3ee1-2ede-4a82-ac9d-aa8b0105dc54 --><h2>Erythromycin</h2><!-- end field 3ecd3ee1-2ede-4a82-ac9d-aa8b0105dc54 -->","summary":"","htmlStringContent":"<!-- begin item a67c3706-afa4-47c4-8ff6-aa8b0105dbe2 --><!-- end item a67c3706-afa4-47c4-8ff6-aa8b0105dbe2 -->","topic":{"id":"ae03d3aa-8b14-5b48-b837-2390b93d3b8c","topicId":"473ddaff-d0fe-4ba6-950d-21174782d383","topicName":"Chest infections - adult","slug":"chest-infections-adult","lastRevised":"Last revised in January 2021","chapters":[{"id":"90a18d8c-865e-5bc5-b97d-7cc8e2e8b178","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"e2a677e7-c782-5648-b8d3-af6f98f5ebf1","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"69d49ed5-19e9-5ca2-afb8-c08c815e9bd2","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"8d6a0737-dbc9-5f75-9d78-66599e03b11a","slug":"changes","fullItemName":"Changes"},{"id":"4e71b8d1-9ea4-57ff-8862-79109a739b30","slug":"update","fullItemName":"Update"}]},{"id":"c97ad137-7a88-5cd3-8a35-9f8609bc27e3","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"c3eaa151-d5d8-59ae-82d9-c89db380b247","slug":"goals","fullItemName":"Goals"},{"id":"73a8fdad-99ee-5ab8-a499-cd210cbe2ea7","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"f1989250-5170-573a-8d73-ccbd23325cc4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"698f6236-86b5-5358-b8f6-3d986ce6e62c","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7998bfca-0c1f-51aa-874d-18dd62dc65b5","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"2547690c-ac67-5a70-874e-e724acc82aad","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"b6392ff8-168f-5ece-b043-720dc73b7fdb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"68203533-e202-5c04-b713-4d1f99e43d13","slug":"definition","fullItemName":"Definition"},{"id":"f05dcc7a-8622-5d0d-ba44-1a07f067c697","slug":"causes","fullItemName":"Causes"},{"id":"6dafb8b2-4871-5b47-ae51-7072fd0797ba","slug":"prevalence","fullItemName":"Prevalence"},{"id":"4f0c5b3d-3b3c-5c08-9f1d-f0fa9ed78995","slug":"complications-prognosis","fullItemName":"Complications and prognosis"}]},{"id":"dd5c4b0b-5449-5a20-b4b9-c1956ff731da","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"f8e2ad44-e229-588b-9421-5abb8d1366eb","slug":"assessment","fullItemName":"Assessment"},{"id":"8d401a7c-ada5-5bca-be9b-e0bde92f64d5","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"88bc2ad2-e15f-55af-a18a-db25d508dc89","fullItemName":"Management","slug":"management","subChapters":[{"id":"4ecbb38d-ec8f-5460-a468-aa870d049dfd","slug":"acute-bronchitis","fullItemName":"Scenario: Acute bronchitis"},{"id":"2afcbc23-a523-58d2-a490-ccfd81a2ce35","slug":"community-acquired-pneumonia","fullItemName":"Scenario: Community-acquired pneumonia"},{"id":"8782a14a-80d3-50d3-ab1b-9cc97e1fa22f","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"22189471-b7cd-534f-90d1-330da8d043b0","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"519bb329-75b0-5c14-84b8-9e6f162dcd2b","slug":"analgesia","fullItemName":"Analgesia"},{"id":"9e7786da-9ac8-50aa-bbac-6e15a0be127c","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"8cf724ea-6c07-5198-9916-b9d96d97acd2","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"4a74695a-622a-5bd3-b14f-cad47d602084","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"b500954c-b6b0-5e3b-ac55-0c2c6e2faf4c","slug":"erythromycin","fullItemName":"Erythromycin"}]},{"id":"8d0f9e0d-aea2-55e1-b4c1-b92b4c8161c4","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"96b9722b-40c5-5b7f-94ad-4223eb0a35e1","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"675135a4-558c-55ca-bcea-3c1d902517c3","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"e36b3e2e-a318-543d-bec5-980aa965fcc6","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"0cdeaef3-f31b-5054-8e9e-7589311e7281","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"a75aec21-edc0-55f4-810d-3cf44899b423","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"4085970a-642c-5d31-8c9f-414c768e84cb","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"76c4843c-7c5d-5f73-9c52-81b55b85ce03","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"22189471-b7cd-534f-90d1-330da8d043b0","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"04ac1a83-b731-5fa1-94de-2c7a5eae374b","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 98e66d96-eca9-4ea4-b89c-aa8d0142725f --><h3>What contraindications and cautions are important with erythromycin?</h3><!-- end field 98e66d96-eca9-4ea4-b89c-aa8d0142725f -->","summary":"","htmlStringContent":"<!-- begin item 3295f658-0136-41a7-8c6d-aa8d01427227 --><!-- begin field 6bc283a3-33f5-41d3-a7e2-aa8d0142725f --><ul><li><strong>Do not prescribe e</strong><strong>rythromycin</strong> to people with:<ul><li>Known hypersensitivity to erythromycin.</li><li>Porphyria.</li><li>A history of QT interval prolongation or ventricular cardiac arrhythmia.</li><li>Conditions that predispose to QT interval prolongation such as electrolyte disturbances and people taking drugs that prolong the QT interval.</li></ul></li><li><strong>Prescribe erythromycin with caution in people with:</strong><ul><li>Renal impairment.</li><li>Impaired hepatic function (or people concomitantly receiving potentially hepatotoxic drugs) — erythromycin is principally excreted by the liver. </li><li>Myasthenia gravis — erythromycin may aggravate the symptoms of people with myasthenia gravis.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chest-infections-adult/references/\">ABPI, 2018d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chest-infections-adult/references/\">Joint Formulary Committee, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chest-infections-adult/references/\">MHRA, 2020</a>]</p><!-- end field 6bc283a3-33f5-41d3-a7e2-aa8d0142725f --><!-- end item 3295f658-0136-41a7-8c6d-aa8d01427227 -->","subChapters":[]},{"id":"f4da9921-18e0-5c82-b0f1-526dbc56e8d4","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field e538f2c6-a783-4a4d-a5ef-aa8d014283e6 --><h3>What are the adverse effects of erythromycin?</h3><!-- end field e538f2c6-a783-4a4d-a5ef-aa8d014283e6 -->","summary":"","htmlStringContent":"<!-- begin item 36c976e3-8c52-480e-bfa6-aa8d014283bd --><!-- begin field 9c2f79c0-f002-4874-8409-aa8d014283e6 --><ul><li><strong>Gastrointestinal symptoms</strong> are the most common adverse effects of macrolides, for example nausea, vomiting, abdominal discomfort, and diarrhoea. Other gastrointestinal effects that have been reported include pancreatitis and anorexia.<ul><li>Consider pseudomembranous colitis if a person develops diarrhoea during or after treatment with erythromycin. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>. </li></ul></li><li><strong>Anaphylaxis</strong> has been reported to occur with erythromycin. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a>.  </li><li>Other adverse effects include:<ul><li><strong>Hepatobiliary disorders, </strong>for example cholestatic or hepatocellular hepatitis, jaundice, hepatomegaly, hepatic dysfunction.</li><li><strong>Cardiac disorders, </strong>for example QT interval prolongation, palpitations, and arrhythmias.</li><li><strong>Skin disorders</strong>, for example urticaria, rash, erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis.</li><li><strong>Reversible hearing loss, tinnitus.</strong></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chest-infections-adult/references/\">ABPI, 2018d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chest-infections-adult/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 9c2f79c0-f002-4874-8409-aa8d014283e6 --><!-- end item 36c976e3-8c52-480e-bfa6-aa8d014283bd -->","subChapters":[]},{"id":"112a8528-571f-5a3d-a829-0f8ff5837399","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field a74a75ae-cf27-4d38-8f8b-aa8d0142914d --><h3>What drug interactions are important with erythromycin?</h3><!-- end field a74a75ae-cf27-4d38-8f8b-aa8d0142914d -->","summary":"","htmlStringContent":"<!-- begin item aeaa4d88-8c8e-4eee-b7f9-aa8d0142912d --><!-- begin field 0c94590b-25cd-43c2-b9f9-aa8d0142914d --><ul><li><strong>Carbamazepine </strong>— erythromycin markedly increases the concentration of carbamazepine. Monitor carbamazepine levels and adjust the dose.</li><li><strong>Calcium channel blockers (CCBs)</strong> — hypotension, bradyarrythmias and lactic acidosis have been reported in people taking erythromycin and verapamil. Erythromycin is also predicted to increase exposure to other CCBs. </li><li><strong>Contraceptives</strong> — additional contraceptive precautions are <em>not</em> required during or after a course of erythromycin.<ul><li>However, advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the section on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>. </li></ul></li><li><strong>Drugs that prolong the QT interval </strong>(such as amiodarone, or sotalol) — erythromycin can prolong the QT interval, and concomitant use of erythromycin and drugs that prolong the QT interval should be avoided.</li><li><strong>Drugs that cause hypokalaemia (such as diuretics, prednisolone). </strong>Hypokalaemia is a risk factor for torsade de pointes arrhythmias.</li><li><strong>Edoxaban</strong> — erythromycin slightly increases exposure to edoxaban and the edoxaban dose may need to be adjusted. </li><li><strong>Statins</strong> — erythromycin is an inhibitor of liver isoenzyme cytochrome P450 CYP3A4, which is particularly involved in the metabolism of simvastatin and atorvastatin. The risk of myopathy and/or rhabdomyolysis is increased with higher plasma concentrations of statins.<ul><li>For simvastatin — do not prescribe erythromycin to a person taking simvastatin. If treatment with erythromycin cannot be avoided, stop treatment with simvastatin during the course of the treatment.</li><li>For atorvastatin — avoid concurrent use with erythromycin. If concurrent use cannot be avoided, prescribe the lowest dose of atorvastatin, and advise the person to report any muscle pain, tenderness, or weakness, or dark coloured urine.</li><li>Other statins — fluvastatin, pravastatin, and rosuvastatin are not metabolised by cytochrome P450 3A4, but until more information is available about other potential mechanisms of interaction, these drugs should be used with caution in combination with erythromycin and the person should be advised to report any muscle pain, tenderness, or weakness, or dark coloured urine (signs of myopathy).</li></ul></li><li><strong>Theophylline</strong> — erythromycin increases serum concentrations of theophylline, and theophylline may also reduce the clearance of erythromycin. Monitor and adjust the theophylline dosage as necessary</li><li><strong>Rivaroxaban </strong>— erythromycin may increase levels of rivaroxaban, increasing the risk of bleeding. </li><li><strong>Warfarin</strong> — the anticoagulant effect of warfarin may be increased by erythromycin. Monitor the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/chest-infections-adult/references/\">FSRH, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chest-infections-adult/references/\">ABPI, 2018d</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chest-infections-adult/references/\">UKMi, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chest-infections-adult/references/\">Joint Formulary Committee, 2019</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/chest-infections-adult/references/\">MHRA, 2020</a>]</p><!-- end field 0c94590b-25cd-43c2-b9f9-aa8d0142914d --><!-- end item aeaa4d88-8c8e-4eee-b7f9-aa8d0142912d -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}